Actively Recruiting
Postoperative Pain Control With Intertransverse Process Block in Patients Undergoing Thoracotomy With Lobectomy
Led by Konya City Hospital · Updated on 2026-04-09
66
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of the intertransverse process block (ITPB) for reducing postoperative pain in patients undergoing elective thoracotomy with unilateral lobectomy. This prospective, randomized, triple-blind, placebo-controlled trial aims to assess how well ITPB manages pain and reduces opioid use while ensuring safety and following routine clinical care practices. The study is conducted at a single tertiary center with participants providing written consent. Participants are randomly assigned to one of two groups: one group receives an ultrasound-guided ITPB with 0.5% bupivacaine, and the other group receives a placebo injection of normal saline. The block is performed immediately after surgery and before waking from anesthesia by an experienced anesthesiologist. Both groups receive standardized general anesthesia, multimodal pain control around the time of surgery, and postoperative intravenous morphine through a patient-controlled analgesia (PCA) device. During the study, researchers will monitor participants' pain levels using numerical rating scores, track morphine consumption in the first 24 hours after surgery, and record any additional pain relief needed or adverse events. Participants must be able to use the PCA device and will be observed at regular intervals during their hospital stay, which is expected to be at least one night. The trial will help determine the analgesic benefits and safety of ITPB in this surgical setting.
CONDITIONS
Brief Title
Intertransverse Process Block for Postoperative Analgesia After Thoracotomy and Lobectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provision of written informed consent
- Age between 18 and 85 years
- ASA Physical Status classification I-III
- Elective thoracotomy with planned unilateral lobectomy
- Anticipated hospital stay of at least one night
- Expected requirement for parenteral opioid analgesia for at least 24 hours postoperatively
- Ability to operate an intravenous patient-controlled analgesia (PCA) device
You will not qualify if you...
- Patients undergoing emergency surgery
- Presence of infection or open wound at the injection site
- Coagulopathy
- Hepatic or renal failure
- Patients undergoing reoperation
- Patients with missing or incomplete data
- Pregnancy or lactation
- Tracheal malformation or tracheostomy
- Chronic opioid use (≥30 days within the last 3 months, ≥15 mg/day morphine equivalent)
- Patients exceeding the maximum safe local anesthetic dose based on weight (2.5 mg/kg, max 150 mg)
- Patients who refuse data privacy consent will be excluded from the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 24 hours post-surgery
Participants undergo thoracotomy with lobectomy surgery followed by either an intertransverse process block or a placebo block performed under ultrasound guidance immediately after surgery before anesthesia emergence.
1 surgery visit and observation during the first 24 hours postoperatively
Trial Site Locations
Total: 1 location
1
Konya City Hospital
Konya, Turkey (Türkiye)
Actively Recruiting
Research Team
O
Omer Keklicek, Principal Investigator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here